The National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s Zejula (niraparib) for routine use in the national health service (NHS) for patients with some forms of ovarian, fallopian tube and peritoneal cancer in final draft guidance published on 24th February 2022. Notably, the drug had been funded via the Cancer Drugs Fund (CDF) whilst further evidence was gathered to assess its clinical and cost-effectiveness.
Jenniffer Prescott, programme director in the centre for health technology evaluation at NICE commented, “Today represents a landmark day. Following the introduction of new arrangements for the Cancer Drugs Fund in 2016, we have been able to recommend managed access for a significant number of treatments within the Fund. Niraparib is the 20th treatment that has completed this process and I am delighted we are able to recommend it for people with these forms of cancer”.
An estimated 400 patients with some form of ovarian, fallopian or peritoneal cancer will now have routine access to Zejula.
www.nice.org.uk, “Once-a-day capsule for people with some forms of ovarian, fallopian tube and peritoneal cancer recommended for routine use in the NHS”, 24th February 2022